BCG017 / Biocytogen - LARVOL DELTA

Preclinical evaluation of BCG017, a novel bispecific ADC targeting PTK7 and EGFR (AACR 2026) - "These results highlight the promising efficacy of BCG017 in preclinical models, indicating improved tumor selectivity and suggesting that it could address the limitations of EGFR-targeting therapies while expanding treatment options for PTK7 and EGFR co-expressed settings."

ADC • Bispecific • Preclinical • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • EGFR • PTK7

BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models (AACR 2024) - "BCG017 demonstrated superior anti-tumor activity compared to benchmarks and its PTK7 parental ADC in cell-derived non-small-cell lung cancer (NSCLC) xenografts, and showed enhanced anti-tumoractivity when compared to benchmark ADCs and parental ADCs in patient-derived breast and pancreatic ductal adenocarcinoma xenograft models. These results suggest that BCG017 have the potential to be a novel therapeutic alternative for PTK7 and EGFR co-expressing tumors."

Clinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • EGFR • PTK7